Ingrid A Mayer

Ingrid A Mayer

UNVERIFIED PROFILE

Are you Ingrid A Mayer?   Register this Author

Register author
Ingrid A Mayer

Ingrid A Mayer

Publications by authors named "Ingrid A Mayer"

Are you Ingrid A Mayer?   Register this Author

92Publications

3267Reads

31Profile Views

Nicotinic treatment of post-chemotherapy subjective cognitive impairment: a pilot study.

J Cancer Surviv 2019 Jul 23. Epub 2019 Jul 23.

Center for Cognitive Medicine, Department of Psychiatry and Behavioral Sciences, Vanderbilt University Medical Center, 1601 23rd Ave. South, Nashville, TN, 37212, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11764-019-00786-6DOI Listing
July 2019

Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer.

N Engl J Med 2019 06 3;380(25):2395-2405. Epub 2019 Jun 3.

From Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY (J.A.S., D.F.M.); Dana-Farber Cancer Institute, Boston (R.J.G.); University of Texas, San Antonio (P.M.R.); Sunnybrook Research Institute, Toronto (K.I.P.), and McMaster University, Hamilton, ON (T.J.W.) - both in Canada; Loyola University Medical Center, Maywood (K.S.A.), and Northwestern University, Chicago (L.I.W., V.G.K.) - both in Illinois; University of Michigan, Ann Arbor (D.F.H.); Virginia Commonwealth University School of Medicine and the Massey Cancer Center, Richmond (C.E.G.); University of North Carolina, Chapel Hill (E.C.D.), and Duke University Medical Center, Durham (J.A.O., J.A.) - both in North Carolina; Mayo Clinic, Jacksonville, FL (M.P.G.); National Institutes of Health, National Cancer Institute, Bethesda, MD (T.L.); Indiana University School of Medicine (S.S.B.) and Indiana University Hospital (G.W.S.), Indianapolis; Vince Lombardi Cancer Clinic, Two Rivers (T.J.S.), and Fox Valley Hematology and Oncology, Appleton (T.F.G.) - both in Wisconsin; Washington University, St. Louis (M.J.E.); the National Surgical Adjuvant Breast and Bowel Project Pathology Office (S.P.) and the University of Pittsburgh (A.M.B.), Pittsburgh; Emory University, Atlanta (W.C.W.); Cancer Trials Ireland, Dublin (M.M.K.); Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru (H.L.G.M.); Cancer Center of Kansas, Wichita (P.S.R.); Vanderbilt University, Nashville (I.A.M.); Rutgers Cancer Institute of New Jersey, New Brunswick (D.L.T.); and the University of Hawaii Cancer Center, Honolulu (J.L.B.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1904819DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6709671PMC
June 2019

Sacituzumab Govitecan-hziy in Triple-Negative Breast Cancer. Reply.

N Engl J Med 2019 06;380(24):2382

New York-Presbyterian-Columbia University Irving Medical Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1903943DOI Listing
June 2019

Alpelisib for -Mutated, Hormone Receptor-Positive Advanced Breast Cancer.

N Engl J Med 2019 05;380(20):1929-1940

From Institut Gustave Roussy, INSERM Unité 981, Université Paris-Sud, Villejuif (F.A.), Institut de Cancérologie de l'Ouest, St. Herblain (M.C.), and Novartis Pharma, Paris (A.-S.L.) - all in France; Hospital Universitario 12 de Octubre, Madrid (E.C.); National Institute of Oncology (G.R.) and Duna Medical Center (Z.P.), Budapest, Hungary; German Breast Group, Neu-Isenburg, and Center for Hematology and Oncology Bethanien, Frankfurt - both in Germany (S.L.); UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco (H.S.R.); Aichi Cancer Center, Nagoya (H.I.), Kanagawa Cancer Center, Yokohama (T.Y.), Saitama Cancer Center, Saitama (K.I.), and National Hospital Organization Hokkaido Cancer Center, Sapporo (M.T.) - all in Japan; Istituto Oncologico Veneto and the Departments of Surgery, Oncology, and Gastroenterology, University of Padua, Padua, Italy (P.C.); Vanderbilt University, Nashville (I.A.M.); Chaim Sheba Medical Center, Tel Hashomer, Israel (B.K.); National Taiwan University Hospital, Taipei (Y.-S.L.); Novartis Pharma, Basel, Switzerland (D.M., C.W.); Novartis Pharmaceuticals, East Hanover, NJ (S.H.); and Massachusetts General Hospital Cancer Center, Boston (D.J.).

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMoa1813904
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1813904DOI Listing
May 2019

Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer.

N Engl J Med 2019 02;380(8):741-751

From the Massachusetts General Hospital Cancer Center (A.B., S.J.I.) and Dana-Farber Cancer Institute (S.M.T.), Harvard Medical School, Boston; Vanderbilt-Ingram Cancer Center, Nashville (I.A.M., V.G.A.); Weill Cornell Medical College (L.T.V.) and New York-Presbyterian-Columbia University Irving Medical Center (K.K.), New York; University of Colorado Cancer Center, Aurora (J.R.D.); Texas Oncology, Baylor University Medical Center, US Oncology, Dallas (J.O.); Orlando Health University of Florida Health Cancer Center, Orlando (R.L.M., N.C.S.); Yale University School of Medicine, New Haven, CT (A.D.S.); University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco (H.S.R.); Immunomedics, Morris Plains, NJ (D.M.G., R.I., S.W., R.M.S., W.A.W.); and AIS Consulting, Ann Arbor, MI (A.M.S.).

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMoa1814213
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1814213DOI Listing
February 2019

Double-Blind Phase III Trial of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node-Positive and High-Risk Lymph Node-Negative Breast Cancer (E5103).

J Clin Oncol 2018 09 24;36(25):2621-2629. Epub 2018 Jul 24.

Kathy D. Miller, Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Anne O'Neill, Dana-Farber Cancer Institute, Boston, MA; William Gradishar, Northwestern University, Chicago; Nguyet Anh Le-Lindqwister, Heartland Cancer Research National Cancer Institute Community Oncology Research Program, Peoria, IL; Timothy J. Hobday, Mayo Clinic, Rochester; Stuart Bloom, Abbott Northwestern Hospital, Minneapolis, MN; Lori J. Goldstein, Fox Chase Cancer Center, Philadelphia; Adam M. Brufsky, University of Pittsburgh, Pittsburgh, PA; Ingrid A. Mayer, Vanderbilt University, Nashville, TN; Amye J. Tevaarwerk, University of Wisconsin, Madison, WI; Joseph A. Sparano, Montefiore Hospital and Medical Center, Bronx; Chau T. Dang, Memorial Sloan Kettering Cancer Center, New York, NY; Carolyn B. Hendricks, Association Community Clinical Oncology Program, Bethesda, MD; Donald W. Northfelt, Mayo Clinic, Scottsdale, AZ; and George W. Sledge JR, Stanford University, Stanford, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2018.79.2028DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6118403PMC
September 2018

Paclitaxel With Inhibitor of Apoptosis Antagonist, LCL161, for Localized Triple-Negative Breast Cancer, Prospectively Stratified by Gene Signature in a Biomarker-Driven Neoadjuvant Trial.

J Clin Oncol 2018 Sep 20:JCO2017748392. Epub 2018 Sep 20.

Aditya Bardia, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston; Scott Cameron and Serena Liao, Novartis Institutes for BioMedical Research, Cambridge, MA; Marina Parton, The Royal Marsden Hospital, London, United Kingdom; Sherko Kümmel, Kliniken Essen-Mitte, Essen, Germany; Laura G. Estévez, Centro Integral Oncológico Clara Campal; Javier Cortés, University Hospital Ramón y Cajal, Madrid; Javier Cortés,Vall d'Hebron Institute of Oncology, Barcelona; Manuel Ruiz-Borrego, Hospital Universitario Virgen del Rocío, Seville; Paloma Martin-Martorell, Hospital Clínico Universitario de Valencia, Valencia; Rafael López, Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain; Chiun-Sheng Huang, National Taiwan University Hospital, National Taiwan University College of Medicine; Shin-Cheh Chen, Chang Gung Memorial Hospital, Taipei, Republic of China; Melinda L. Telli, Stanford University School of Medicine, Stanford; Sara A. Hurvitz, UCLA Jonsson Comprehensive Cancer Center, Los Angeles, CA; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Roohi Ismail-Khan, Moffitt Cancer Center, Tampa, FL; Ingrid A. Mayer, Vanderbilt-Ingram Cancer Center, Nashville, TN; Daniel Carreon, Novartis Pharmaceuticals Corporation, East Hanover, NJ; José Baselga, Memorial Sloan Kettering Cancer Center, New York, NY; and Sung-Bae Kim, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2017.74.8392
Publisher Site
http://dx.doi.org/10.1200/JCO.2017.74.8392DOI Listing
September 2018

Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer.

N Engl J Med 2018 Jul 3;379(2):111-121. Epub 2018 Jun 3.

From Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY (J.A.S., D.F.M.); Dana-Farber Cancer Institute, Boston (R.J.G.); Sunnybrook Research Institute, Toronto (K.I.P.), and McMaster University, Hamilton, ON (T.J.W.) - both in Canada; Loyola University Chicago Stritch School of Medicine, Maywood (K.S.A.), and Northwestern University, Chicago (L.I.W., V.G.K.) - both in Illinois; University of Michigan, Ann Arbor (D.F.H.); Virginia Commonwealth University School of Medicine and the Massey Cancer Center, Richmond (C.E.G.); University of North Carolina, Chapel Hill (E.C.D.), and Duke University Medical Center, Durham (J.A.O.) - both in North Carolina; Mayo Clinic, Jacksonville, FL (M.P.G.); National Institutes of Health, National Cancer Institute, Bethesda, MD (T.L., J.A.); Indiana University School of Medicine (S.S.B.) and Indiana University Hospital (G.W.S.), Indianapolis; Vince Lombardi Cancer Clinic, Two Rivers (T.J.S.), and Fox Valley Hematology and Oncology, Appleton (T.F.G.) - both in Wisconsin; Washington University, St. Louis (M.J.E.); National Surgical Adjuvant Breast and Bowel Project Pathology Office (S.P.) and University of Pittsburgh (A.M.B.), Pittsburgh; Emory University, Atlanta (W.C.W.); University of Texas, San Antonio (P.M.R.); Cancer Trials Ireland, Dublin (M.M.K.); Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru (H.L.G.M.); Cancer Center of Kansas, Wichita (P.S.R.); Vanderbilt University, Nashville (I.A.M.); Rutgers Cancer Institute of New Jersey, New Brunswick (D.L.T.); and University of Hawaii Cancer Center, Honolulu (J.L.B.).

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMoa1804710
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1804710DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6172658PMC
July 2018

Motivation for Launching a Cancer Metastasis Inhibition (CMI) Program.

Target Oncol 2018 02;13(1):61-68

Department of Cell and Developmental Biology, Vanderbilt University School of Medicine, 465 21st Avenue South, Nashville, TN, 37232, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11523-017-0542-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5826865PMC
February 2018

Novel Targeted Agents and Immunotherapy in Breast Cancer.

Am Soc Clin Oncol Educ Book 2017 ;37:65-75

From the Vanderbilt University Medical Center, Nashville, TN; Division of Medical Oncology, National Cancer Centre Singapore, Singapore; Duke-NUS Medical School, Singapore, Singapore; Peter MacCallum Cancer Centre, Melbourne, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EDBK_175631DOI Listing
December 2017

Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer.

J Clin Oncol 2017 Jul 14;35(19):2141-2148. Epub 2017 Mar 14.

Aditya Bardia, Steven J. Isakoff, and Dejan Juric, Massachusetts General Hospital Cancer Center; Aditya Bardia, Steven J. Isakoff, Dejan Juric, and Sara M. Tolaney, Harvard Medical School; Sara M. Tolaney, Dana-Farber Cancer Institute, Boston, MA; Ingrid A. Mayer, Vandana Abramson, and Jordan Berlin, Vanderbilt-Ingram Cancer Center, Nashville, TN; Jennifer R. Diamond and Wells A. Messersmith, University of Colorado Cancer Center, Aurora, CO; Rebecca L. Moroose and Nikita C. Shah, University of Florida Health Cancer Center, Orlando, FL; Alexander N. Starodub, Indiana University Health Center for Cancer Care, Goshen, IN; Joyce O'Shaughnessy, Texas Oncology-Baylor Charles A. Sammons Cancer Center; Joyce O'Shaughnessy, US Oncology, Dallas, TX; Kevin Kalinsky, Columbia University Herbert Irving Comprehensive Cancer Center; Allyson J. Ocean and Linda T. Vahdat, Weill Cornell Medicine, New York, NY; Michael Guarino, Helen F. Graham Cancer Center, Newark, DE; William A. Wegener, Pius Maliakal, Robert M. Sharkey, Serengulam V. Govindan, and David M. Goldenberg, Immunomedics, Morris Plains, NJ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.70.8297DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5559902PMC
July 2017

A Case Report of Severe Type B Lactic Acidosis Following First Dose of Nivolumab in a VHL-Mutated Metastatic Renal Cell Carcinoma.

Kidney Cancer 2017 Jul 26;1(1):83-88. Epub 2017 Jul 26.

Division of Hematology and Oncology, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/KCA-160004DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6179105PMC
July 2017

A 3q gene signature associated with triple negative breast cancer organ specific metastasis and response to neoadjuvant chemotherapy.

Sci Rep 2017 04 7;7:45828. Epub 2017 Apr 7.

Division of Pulmonary and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/srep45828DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5384279PMC
April 2017

PI3K/AKT/mTOR: role in breast cancer progression, drug resistance, and treatment.

Cancer Metastasis Rev 2016 12;35(4):515-524

Departments of Medicine and Cancer Biology; Breast Cancer Program, Vanderbilt-Ingram, Cancer Center, Vanderbilt University School of Medicine, Nashville, TN, 37232, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10555-016-9637-xDOI Listing
December 2016

Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease.

Nat Rev Clin Oncol 2016 Nov 17;13(11):674-690. Epub 2016 May 17.

Department of Medical Oncology, IRCCS Ospedale San Raffaele, Via Olgettina 60, Milan, 20132 Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2016.66DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5461122PMC
November 2016

The PI3K/AKT Pathway as a Target for Cancer Treatment.

Annu Rev Med 2016 14;67:11-28. Epub 2015 Oct 14.

Departments of Medicine and Cancer Biology; Breast Cancer Program, Vanderbilt-Ingram Cancer Center; Vanderbilt University School of Medicine, Nashville, Tennessee 37232; email: ,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1146/annurev-med-062913-051343DOI Listing
October 2016

Is There a Future for AKT Inhibitors in the Treatment of Cancer?

Clin Cancer Res 2016 06 15;22(11):2599-601. Epub 2016 Mar 15.

Breast Cancer Program, Vanderbilt-Ingram Cancer Center (VICC), Vanderbilt University, Nashville, Tennessee.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-16-0100DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4891224PMC
June 2016

NCCN Guidelines Insights Breast Cancer, Version 1.2016.

J Natl Compr Canc Netw 2015 Dec;13(12):1475-85

From Robert H. Lurie Comprehensive Cancer Center of Northwestern University; University of Washington/Seattle Cancer Care Alliance; UCSF Helen Diller Family Comprehensive Cancer Center; UC San Diego Moores Cancer Center; Dana-Farber/Brigham and Women's Cancer Center; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; University of Colorado Cancer Center; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; University of Alabama at Birmingham Comprehensive Cancer Center; The University of Texas MD Anderson Cancer Center; Mayo Clinic Cancer Center; Fox Chase Cancer Center; Memorial Sloan Kettering Cancer Center; Massachusetts General Hospital Cancer Center; Duke Cancer Institute; Vanderbilt-Ingram Cancer Center; Yale Cancer Center/Smilow Cancer Hospital; University of Michigan Comprehensive Cancer Center; Fred & Pamela Buffett Cancer Center; Roswell Park Cancer Institute; St. Jude Children's Research Hospital/The University of Tennessee Health Science Center; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Research Advocacy Network; Moffitt Cancer Center; City of Hope Comprehensive Cancer Center; Stanford Cancer Institute; Huntsman Cancer Institute at the University of Utah; and National Comprehensive Cancer Network.

View Article

Download full-text PDF

Source
December 2015

Clinical Implications of Mutations in the PI3K Pathway in HER2+ Breast Cancer: Prognostic or Predictive?

Authors:
Ingrid A Mayer

Curr Breast Cancer Rep 2015 Dec 10;7(4):210-214. Epub 2015 Oct 10.

Department of Medicine, Breast Cancer Program, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN, USA; Division of Hematology/Oncology, Vanderbilt University Medical Center/Vanderbilt-Ingram Cancer Center, 2220 Pierce Avenue, 777 PRB, Nashville, TN 37232-6307, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12609-015-0197-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4751984PMC
December 2015

Prospective Validation of a 21-Gene Expression Assay in Breast Cancer.

N Engl J Med 2015 Nov 27;373(21):2005-14. Epub 2015 Sep 27.

From the Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY (J.A.S., D.F.M.); Dana-Farber Cancer Institute, Boston (R.J.G.); Sunnybrook Research Institute, Toronto (K.I.P.) and Juravinski Cancer Center, Hamilton, ON (T.J.W.) - both in Canada; Loyola University Medical Center, Maywood (K.S.A.), and Northwestern University, Chicago (L.I.W., V.G.K.) - both in Illinois; University of Michigan, Ann Arbor (D.F.H.); Virginia Commonwealth University School of Medicine and the Massey Cancer Center, Richmond (C.E.G.); University of North Carolina, Chapel Hill (E.C.D.), Duke University Medical Center, Durham (J.A.O.), Wake Forest University Health Service, Winston-Salem (L.I.W.), and Southeast Clinical Oncology Research Consortium, Goldsboro (J.N.A.) - all in North Carolina; Mayo Clinic, Jacksonville, FL (E.A.P.); University of Maryland School of Medicine, Baltimore (J.A.O.), and National Institutes of Health, Bethesda (J.Z., T.L.) - both in Maryland; Indiana University School of Medicine (S.S.B.) and Indiana University Hospital (G.W.S.) - both in Indianapolis; Vince Lombardi Cancer Clinic, Two Rivers (T.J.S.), and Fox Valley Hematology and Oncology, Appleton (T.F.G.) - both in Wisconsin; Baylor College of Medicine, Houston (M.J.E.), and University of Texas, San Antonio (P.R.) - both in Texas; Washington University, St. Louis (M.J.E.); Allegheny General Hospital (S.P.) and University of Pittsburgh (A.M.B.) - both in Pittsburgh; the Department of Medical Oncology and Breast Center, Yonsei University College of Medicine, Seoul, South Korea (S.P.); Emory University, Atlanta (W.C.W.); Irish Clinical Oncology Research Group, Dublin (M.M.K.); Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru (H.L.G.M.); Cancer Center of Kansas, Wichita (P.S.R.); Vanderbilt University, Nashville (I.A.M.); Rutgers Cancer Institute of New Jersey, New Brunswick (D.L.T.); University of Hawaii Cancer Center, Honolulu (J.L.B.); and Stanford University, Stanford, CA (G.W.S.)

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1510764DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4701034PMC
November 2015

Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [18F]Fluorodeoxyglucose Positron Emission Tomography Imaging (TBCRC 003).

J Clin Oncol 2015 Aug 13;33(24):2623-31. Epub 2015 Jul 13.

Nancy U. Lin, Hao Guo, Nicole Ryabin, Julie S. Najita, William T. Barry, Ian E. Krop, Eric P. Winer, and Annick D. Van den Abbeele, Dana-Farber Cancer Institute; Andrea L. Richardson and Annick D. Van den Abbeele, Brigham and Women's Hospital, Boston, MA; Jeffrey T. Yap, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT; Ingrid A. Mayer and Carlos L. Arteaga, Vanderbilt-Ingram Cancer Center, Nashville, TN; Carla I. Falkson, University of Alabama, Birmingham, AL; Timothy J. Hobday, Mayo Clinic, Rochester, MN; E. Claire Dees, University of North Carolina, Chapel Hill, NC; Rita Nanda, University of Chicago, Chicago, IL; Mothaffar F. Rimawi, Baylor College of Medicine, Houston, TX; and Antonio C. Wolff, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.60.0353DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4534525PMC
August 2015

Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline.

J Clin Oncol 2015 Aug 20;33(24):2695-704. Epub 2015 Jul 20.

Catherine Van Poznak and Daniel F. Hayes, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Mark R. Somerfield, American Society of Clinical Oncology, Alexandria, VA; Robert C. Bast, Ana M. Gonzalez-Angulo, and William F. Symmans, University of Texas MD Anderson Cancer Center, Houston; Robert G. Mennel, Texas Oncology, Dallas, TX; Massimo Cristofanilli, Thomas Jefferson University-Kimmel Cancer Center, Philadelphia, PA; Matthew P. Goetz and Minetta C. Liu, Mayo Clinic, Rochester, MN; David G. Hicks, University of Rochester Medical Center, Rochester, NY; Elizabeth G. Hill, Medical University of South Carolina, Hollings Cancer Center, Charleston, SC; Wanda Lucas, Georgetown University, Washington, DC; Ingrid A. Mayer, Vanderbilt University Medical Center and Vanderbilt-Ingram Cancer Center, Nashville, TN; and Lyndsay N. Harris, Seidman Cancer Center, Case Western Reserve University, Cleveland, OH.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.61.1459DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5478102PMC
August 2015

Optimizing the use of neoadjuvant endocrine therapy.

Curr Oncol Rep 2015 Jul;17(7):33

Department of Medicine, Breast Cancer Research Program, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-015-0455-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5524371PMC
July 2015

Advanced hormone-sensitive breast cancer: overcoming resistance.

Authors:
Ingrid A Mayer

J Natl Compr Canc Netw 2015 May;13(5 Suppl):655-7

Presented by Ingrid A. Mayer, MD, MSCI, Associate Professor of Medicine and Clinical Director of the Breast Cancer Program at Vanderbilt-Ingram Cancer Center, Nashville, Tennessee.

View Article

Download full-text PDF

Source
May 2015

Multiparametric magnetic resonance imaging for predicting pathological response after the first cycle of neoadjuvant chemotherapy in breast cancer.

Invest Radiol 2015 Apr;50(4):195-204

From the *Institute of Imaging Science, †Department of Radiology and Radiological Sciences, ‡the Vanderbilt-Ingram Cancer Center, Departments of §Biostatistics, ∥Radiation Oncology, ¶Medical Oncology, #Surgical Oncology, **Pathology, ††Physics and Astronomy, ‡‡Cancer Biology, and §§Biomedical Engineering, Vanderbilt University, Nashville, TN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/RLI.0000000000000100DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4471951PMC
April 2015

Effect of metformin vs placebo on and metabolic factors in NCIC CTG MA.32.

J Natl Cancer Inst 2015 Mar 4;107(3). Epub 2015 Mar 4.

Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada (PJG); NCIC Clinical Trials Group, Cancer Research Institute, Queen's University, Kingston, Ontario, Canada (WRP, LES, BEC); NCIC Clinical Trials Group, British Columbia Cancer Agency, University of British Columbia, Vancouver, British Columbia, Canada (KAG); Dana Farber Cancer Institute, Harvard Medical School, Boston, MA (JAL); Columbia University Medical Center, New York, NY (DLH); National Surgical Adjuvant Breast and Bowel Project, University of Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh, PA (PR); Vanderbilt-Ingram Medical Center, Vanderbilt University Medical Center, Nashville, TN (IAM); Mayo Clinic College of Medicine, Rochester, MN (TJH); Centre de recherche du CHU de Québec, Unité de recherche en santé des populations Hôpital du Saint-Sacrement, Quebec, Quebec, Canada (JL); National Cancer Research Institute Breast Clinical Studies Group, London, UK (AMT); Sunnybrook Odette Cancer Center, University of Toronto, Toronto, Ontario, Canada (KIP); Juravinski Cancer Center at Hamilton Health Sciences, McMaster University, Hamilton, Ontario, Canada (TJW, SDM); Allan Blair Cancer Centre, Regina, Saskatchewan, Canada (HIC); British Columbia Cancer Agency, Fraser Valley Center, Surrey, British Columbia, Canada (CDO); University of Alberta, Cross Cancer Institute, Edmonton, Alberta, Canada (KST); British Columbia Cancer Agency - Vancouver Island Center, University of British Columbia, British Columbia, Canada (VB); Ontario Cancer Institute, University Health Network, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada (VS).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djv006DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4565534PMC
March 2015

Platinum agents in the treatment of early-stage triple-negative breast cancer: is it time to change practice?

Clin Adv Hematol Oncol 2014 Oct;12(10):654-8

Vanderbilt University School of Medicine, Nashville, TN.

View Article

Download full-text PDF

Source
October 2014

Molecular Heterogeneity of Triple Negative Breast Cancer.

Curr Breast Cancer Rep 2014 Sep;6(3):154-158

Department of Medicine; Breast Cancer Research Program, Vanderbilt-Ingram Cancer Center; Vanderbilt University School of Medicine, Nashville, TN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12609-014-0152-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4235783PMC
September 2014

Sympathetic nervous system alterations with HER2+ antagonism: an early marker of cardiac dysfunction with breast cancer treatment?

Ecancermedicalscience 2014 17;8:446. Epub 2014 Jul 17.

Department of Medicine, Vanderbilt University School of Medicine, Nashville 37232, TN, USA ; Department of Pharmacology, Vanderbilt University School of Medicine, Nashville TN 37232, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3332/ecancer.2014.446DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4118731PMC
August 2014

Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer.

J Clin Oncol 2014 Apr 24;32(12):1202-9. Epub 2014 Mar 24.

Ingrid A. Mayer, Vandana G. Abramson, Justin M. Balko, María Gabriela Kuba, Melinda E. Sanders, and Carlos L. Arteaga, Vanderbilt University, Nashville, TN; Steven J. Isakoff, Massachusetts General Hospital, Boston, MA; Andres Forero, University of Alabama, Birmingham, AL; Jeffrey T. Yap, Huntsman Cancer Institute, Salt Lake City, UT; Annick D. Van den Abbeele and Eric Winer, Dana-Farber Cancer Institute, Boston, MA; Yisheng Li, MD Anderson Cancer Center, Houston, TX; and Lewis C. Cantley, Weill Cornell Medical College, New York, NY.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/early/2014/03/18/JCO.2013.54
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2013.54.0518
Publisher Site
http://dx.doi.org/10.1200/JCO.2013.54.0518DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3986383PMC
April 2014

New strategies for triple-negative breast cancer--deciphering the heterogeneity.

Clin Cancer Res 2014 Feb;20(4):782-90

Authors' Affiliations: Departments of Medicine and Cancer Biology; and Breast Cancer Research Program, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-0583DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3962777PMC
February 2014

Subtyping of triple-negative breast cancer.

Authors:
Ingrid A Mayer

Clin Adv Hematol Oncol 2013 Nov;11(11):731-2

Vanderbilt University Medical Center, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee.

View Article

Download full-text PDF

Source
November 2013

Thrombotic microangiopathy during docetaxel, trastuzumab, and carboplatin chemotherapy for early-stage HER2+ breast cancer: a case report.

Med Oncol 2013 7;30(2):568. Epub 2013 Apr 7.

Department of Internal Medicine, Vanderbilt University Medical Center, D-3100 Medical Center North, Nashville, TN 37232-2358, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12032-013-0568-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3774143PMC
October 2013

Membrane progesterone receptor alpha as a potential prognostic biomarker for breast cancer survival: a retrospective study.

PLoS One 2012 4;7(4):e35198. Epub 2012 Apr 4.

Histopathology core, Atlanta Research & Educational Foundation/Atlanta VA Medical Center, Decatur, Georgia, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0035198PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3319632PMC
August 2012

Improving survival and limiting toxicity: latest advances in treating human epidermal growth factor receptor 2 overexpressing breast cancer.

Ther Adv Med Oncol 2012 May;4(3):139-47

Department of Medicine and Breast Cancer Research Program, Vanderbilt-Ingram Comprehensive Cancer Center, Vanderbilt University School of Medicine, Nashville, TN, USA.

View Article

Download full-text PDF

Source
http://journals.sagepub.com/doi/10.1177/1758834012440834
Publisher Site
http://dx.doi.org/10.1177/1758834012440834DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3349077PMC
May 2012

Clinical utility of serum tumor markers and circulating tumor cell assays in the treatment of breast cancer.

Curr Treat Options Oncol 2011 Dec;12(4):403-11

Division of Hematology/Oncology, Department of Medicine, Vanderbilt University, Vanderbilt-Ingram Cancer Center, Nashville, TN 37212, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11864-011-0164-2
Publisher Site
http://dx.doi.org/10.1007/s11864-011-0164-2DOI Listing
December 2011

Antiangiogenic therapies in early-stage breast cancer.

Clin Breast Cancer 2010 ;10 Suppl 1:E23-31

Department of Medicine and Breast Cancer Research Program, Vanderbilt-Ingram Comprehensive Cancer Center, Vanderbilt University School of Medicine, Nashville, TN 37232, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3816/CBC.2010.s.004DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3471531PMC
October 2010

Does lapatinib work against HER2-negative breast cancers?

Clin Cancer Res 2010 Mar 23;16(5):1355-7. Epub 2010 Feb 23.

Departments of Medicine, Vanderbilt-Ingram Comprehensive Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-09-3223DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3448974PMC
March 2010

Resistance to Trastuzumab in Breast Cancer.

Clin Cancer Res 2009 Dec;15(24):7479-7491

Authors' Affiliations: Department of Medicine, Breast Cancer Research Program, Vanderbilt-Ingram Comprehensive Cancer Center, and Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, Tennessee.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-09-0636DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3471537PMC
December 2009

Treatment of HER2-positive metastatic breast cancer following initial progression.

Authors:
Ingrid A Mayer

Clin Breast Cancer 2009 Jun;9 Suppl 2:S50-7

Department of Medicine and Breast Cancer Research Program, Vanderbilt-Ingram Comprehensive Cancer Center, Vanderbilt University School of Medicine, Nashville, TN 37232, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3816/CBC.2009.s.005DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3457066PMC
June 2009

Evaluation of biological agents targeted at early-stage disease.

Breast Cancer Res 2008 18;10 Suppl 4:S25. Epub 2008 Dec 18.

Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN 37232, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/bcr2185DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2614851PMC
February 2009

Neoadjuvant concurrent paclitaxel and radiation in stage II/III breast cancer.

Clin Cancer Res 2006 Mar;12(5):1570-6

Department of Radiation Oncology, Vanderbilt University Medical Center, Nashville, Tennessee 37232, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-05-2304DOI Listing
March 2006

Targeting cytokine receptors and pathways in the treatment of breast cancer.

Authors:
Ingrid A Mayer

Cancer Treat Res 2005 ;126:243-62

Vanderbilt University School of Medicine, Department of Medicine, Division of Hematology/Oncology, Nashville, TN, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/0-387-24361-5_10DOI Listing
November 2005